Upon completion of this activity, learners will be able to:
- Identify the key elements for evaluating and treating pateints with dylipidemia including lifestyle modification in a clinically useful format.
- To apply both updated clinical trial data and the AACE treatment goals to the treatmen of dyslipdemia.
- To review the properties of all classes of FDA approved lipid lowering pharmaceuticals.
Starts 5/11/2020 | Expires 5/11/2023
This course includes:
- Video presentation by a leading expert
- Pre- and post-exams to measure your understanding
- CME and MOC claiming online
This course is intended for: Endocrinologists, Nurse Practitioners, Physician Assistants, Certified Diabetes Educators, Diabetologists and Lipidologists.
Paul Jellinger, MD, MACE
ACCME CME Credit
The American College of Endocrinology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Endocrinology designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity enables the participant to earn up to 1 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.
Your participation information will be shared with the ACCME, which will in turn report your points to ABIM. Successful completion of a course examination is required to earn ABIM MOC points.
Disclosures/Conflict of Interest
The American Association of Clinical Endocrinology (AACE) remains strongly committed to providing the best available evidence-based clinical information to participants of this educational activity and requires an open disclosure of any potential conflict of interest identified by our faculty members. It is not the intent of AACE to eliminate all situations of potential conflict of interest, but rather to enable those who are working with AACE to recognize situations that may be subject to question by others. All disclosed conflicts of interest are reviewed by the CME Subcommittee to ensure that such situations are properly evaluated and, if necessary, resolved. AACE educational standards pertaining to conflict of interest are intended to maintain the professional autonomy of the clinical experts inherent in promoting a balanced presentation of science. Through our review process, all AACE accredited activities are ensured of independent, objective, scientifically balanced presentations of information. Disclosure of any or no relationships will be made available for all educational activities.
All other faculty, planners and staff have disclosed no relevant financial relationships with commercial interests.
Paul Jellinger, MD, MACE: Amarin, Amgen, Merck, Regeneron - Honorarium
This activity is supported by independent educational grants from Corcept Therapeutics and Strongbridge Biopharma.
The information provided at this accredited activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
Copyright 2020 AACE. All rights reserved. No part of this enduring material may be reproduced or transmitted in any other form or by any other means, electronic or mechanical, without first obtaining written permission from AACE.